Abbott stock surges 3.55% as MiniMed 780G launches with Instinct sensor in Europe

Traders Union
All News
Financial News
Abbott jumps 3.55% today to $93.7

Highlights

Abbott's commercial rollout of the integrated MiniMed 780G system and Instinct sensors across Europe expands its diabetes care leadership and product ecosystem.
Strong Q1 2026 results with a 13.2% increase in Medical Devices revenue and a $21 billion Exact Sciences acquisition signal accelerating growth and institutional interest.
ABT trades with bullish near-term momentum and may consolidate between $91.15 and $97.14, with a 77% probability of further upside despite overbought signals.

Portfolio growth accelerates as MiniMed integration and asset buy fuel optimism

The commercial launch of MiniMed’s 780G automated insulin delivery system, now fully integrated with Abbott’s Instinct sensor and expanded to include the MiniMed Go system with the Instinct Go sensor across Europe, marks a major advance in Abbott’s diabetes care portfolio, according to Tradingview. This new product integration is poised to drive adoption among both patients and healthcare providers, unlocking growth in the medical devices segment and supporting recent momentum. These developments follow Abbott’s strong Q1 2026 results, which featured a 13.2% rise in Medical Devices revenue and the completed $21 billion acquisition of Exact Sciences to strengthen its diagnostics division. Institutional interest is also evident, with MarketBeat reporting that Assenagon Asset Management S.A. increased its stake in Abbott by 303% during the quarter.

Momentum signals diverge as price presses support but triggers overbought alerts

ABT/USD is now trading above its 20-day moving average at $90.83 and its 50-day moving average at $89.73, while remaining well below the 200-day level at $112.99. The Ichimoku Kijun sits at $90.86 and is providing immediate support. On the hourly chart, momentum readings are mixed: the Relative Strength Index (RSI) is at 66.65 (Buy), the Moving Average Convergence Divergence (MACD) signals Buy, the Average Directional Index (ADX) reads Neutral, and the Awesome Oscillator signals Buy. However, there are overbought conditions on the Commodity Channel Index (CCI) and Bull/Bear Power, while the Stochastic RSI shows a Strong Sell. Overall, momentum signals are bullish, but several oscillators warn the rally may be stretched and vulnerable to near-term consolidation.

Upward bias persists as breakout risk outweighs chance of reversal

In the short term, ABT is expected to trade within the $91.15 to $97.14 range over the next several sessions, reflecting typical volatility. There is a 77% probability of further upward movement versus a 23% probability of a pullback, making a deeper reversal less likely in the immediate term. Consolidation is the baseline scenario in this corridor. Should bullish momentum continue, a breakout above resistance could occur, while a break below the Ichimoku Kijun support would increase downside risk toward $91.15.

Anton Kharitonov, expert at Traders Union, views recent price strength in Abbott as rooted in constructive medical device news and a strong earnings print. However, he notes that overbought technical readings and proximity to key resistance caution against chasing the rally. Institutional buying adds credibility, but stretched sentiment and momentum could lead to near-term consolidation. "Until ABT decisively clears $97.14 and avoids slipping below the Ichimoku Kijun, I see the base case as sideways with modest upside — caution is warranted here."

Earlier, analysts noted that bullish momentum had emerged for Abbott, pointing to a potential trend reversal following a period of downside risk. The latest product launches and accelerating institutional inflows further strengthen this shift, making continued upward movement within the current trading range the scenario to watch in the near term.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.